A Safety/Tolerability and PK Study With Azstarys® in Children With ADHD

PHASE4CompletedINTERVENTIONAL
Enrollment

123

Participants

Timeline

Start Date

June 2, 2023

Primary Completion Date

August 29, 2025

Study Completion Date

August 29, 2025

Conditions
Attention Deficit/Hyperactivity Disorder
Interventions
DRUG

Serdexmethylphenidate (SDX) and dexmethylphenidate (d-MPH)

Serdexmethylphenidate (SDX) and dexmethylphenidate (d-MPH)

Trial Locations (20)

30030

iResearch Atlanta, Decatur

30291

Sky Clinical Research Network Group P.C., Union City

31405

CenExel iResearch, LLC, Savannah

32256

Clinical Neuroscience Solutions - Orlando, Jacksonville

32751

Accel Research Sites - Maitland, Maitland

32801

CNS Healthcare - Orlando, Orlando

33166

South Florida Research Phase I-IV INC, Miami Springs

33803

Accel Research Sites - Lakeland, Lakeland

38119

Clinical Neuroscience Solution, Inc, Memphis

59804

Boeson Research, Missoula

63304

St Charles Psychiatric Associates & Midwest Research Group, Saint Charles

68526

Alivation Research, LLC, Lincoln

70115

DelRicht Research - Touro Medical Center, New Orleans

72211

Preferred Research Partners (PRP), Little Rock

75093

AIM Trials, Plano

77401

Houston Clinical Trials, Bellaire

78229

Flourish Research, San Antonio

80112

IMMUNOe International Research Center, Centennial

89128

Center For Psychiatry and Behavioral Medicine Inc, Las Vegas

92805

Advanced Research Center (ARC), Anaheim

All Listed Sponsors
collaborator

Premier Research Group plc

UNKNOWN

collaborator

Prometrika, LLC

INDUSTRY

collaborator

Almac

INDUSTRY

collaborator

Worldwide Clinical Trials

OTHER

lead

Corium, Inc.

INDUSTRY